Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBT (2016 - 2025)

Regenxbio (RGNX) has 12 years of EBT data on record, last reported at -$67.2 million in Q4 2025.

  • For Q4 2025, EBT fell 31.01% year-over-year to -$67.2 million; the TTM value through Dec 2025 reached -$194.0 million, up 14.66%, while the annual FY2025 figure was -$194.0 million, 242351.25% down from the prior year.
  • EBT reached -$67.2 million in Q4 2025 per RGNX's latest filing, down from -$62.0 million in the prior quarter.
  • Across five years, EBT topped out at $307.5 million in Q4 2021 and bottomed at -$76.8 million in Q1 2022.
  • Average EBT over 5 years is -$41.2 million, with a median of -$61.9 million recorded in 2023.
  • The widest YoY moves for EBT: up 859.25% in 2021, down 764.6% in 2021.
  • A 5-year view of EBT shows it stood at $307.5 million in 2021, then tumbled by 119.49% to -$59.9 million in 2022, then dropped by 5.1% to -$63.0 million in 2023, then grew by 18.58% to -$51.3 million in 2024, then plummeted by 31.01% to -$67.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$67.2 million in Q4 2025, -$62.0 million in Q3 2025, and -$70.9 million in Q2 2025.